IP6, Inositol for Breast Cancer Pts taking Chemotherapy

Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study

Ivan Bačić,1 Nikica Družijanić,2 Robert Karlo,1 Ivan Škifić,1 and Stjepan Jagić3 1Department of Surgery, General Hospital Zadar, 23000 Zadar, Croatia

2Department of Surgery, University Hospital Split and University of Split School of Medicine, 21000 Split, Croatia 3Department of Statistics, University of Zadar, 23000 Zadar, Croatia

Corresponding author.

Ivan Bačić: ivan.bacic21@zd.t-com.hr; Nikica Družijanić: ndruzija@kbsplit.hr; Robert Karlo: obert.karlo@zd.t-com.hr; Ivan Škifić: obert.karlo@zd.t-com.hr; Stjepan Jagić: sjagic@unizd.hr

Received December 6, 2009; Accepted February 12, 2010.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prospective, randomized, pilot clinical study was conducted to evaluate the beneficial effects of inositol hexaphosphate (IP6) + Inositol in breast cancer patients treated with adjuvant therapy.

Patients and methods Patients with invasive ductal breast cancer where polychemotherapy was indicated were monitored in the period from 2005-2007. Fourteen patients in the same stage of ductal invasive breast cancer were involved in the study, divided in two randomized groups.

One group was subjected to take IP6 + Inositol while the other group was taking placebo. In both groups of patients the same laboratory parameters were monitored. When the treatment was finished, all patients have filled questionnaires QLQ C30 and QLQ-BR23 to determine the quality of life.

Results Patients receiving chemotherapy, along with IP6 + Inositol did not have cytopenia, drop in leukocyte and platelet counts. Red blood cell counts and tumor markers were unaltered in both groups.

However, patients who took IP6 + Inositol had significantly better quality of life (p = 0.05) and functional status (p = 0.0003) and were able to perform their daily activities.

Conclusion IP6 + Inositol as an adjunctive therapy is valuable help in ameliorating the side effects and preserving quality of life among the patients treated with chemotherapy.

J Exp Clin Cancer Res. 2010; 29(1): 12. Published online 2010 February 12. doi: 10.1186/1756-9966-29-12.

For the entire study:


Ann's NOTE: Once again we must ask WHEN is it time to recommend a nontoxic method, costing very little, that can help reduce the UNWANTED effects of conventional treatment?

Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.